Blockade of complement activation in bullous pemphigoid by using recombinant CD55-CD46 fusion protein
Open Access
- 5 April 2021
- journal article
- letter
- Published by Ovid Technologies (Wolters Kluwer Health) in Chinese Medical Journal
- Vol. 134 (7), 864-866
- https://doi.org/10.1097/cm9.0000000000001312
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Alzheimer's disease identified in a patient with bullous pemphigoid by dementia screening scalesChinese Medical Journal, 2019
- Decreased expression levels of complement regulator CD55 contribute to the development of bullous pemphigoidOncotarget, 2017
- Dysregulation of mCD46 and sCD46 contribute to the pathogenesis of bullous pemphigoidScientific Reports, 2017
- Clinical Features and Practical Diagnosis of Bullous PemphigoidImmunology and Allergy Clinics of North America, 2012
- Complement and cutaneous autoimmune blistering diseasesImmunologic Research, 2008